Back to Search
Start Over
A perfusable vascularized full-thickness skin model for potential topical and systemic applications
- Source :
- Biofabrication, Biofabrication, 2020, 13 (3), pp.035042. ⟨10.1088/1758-5090/abfca8⟩, Biofabrication, IOP Publishing, 2020, 13 (3), pp.035042. ⟨10.1088/1758-5090/abfca8⟩, Tissue Engineering: Parts A, B, and C, Tissue Engineering: Parts A, B, and C, 2022, 13 (3), pp.S472-S473. ⟨10.1088/1758-5090/abfca8⟩
- Publication Year :
- 2020
- Publisher :
- HAL CCSD, 2020.
-
Abstract
- Vascularization of reconstructed tissues is one of the remaining hurdles to be considered to improve both the functionality and viability of skin grafts and the relevance of in vitro applications. Our study, therefore, sought to develop a perfusable vascularized full-thickness skin equivalent that comprises a more complex blood vasculature compared to existing models. We combined molding, auto-assembly and microfluidics techniques in order to create a vascularized skin equivalent representing (a) a differentiated epidermis with a physiological organization and correctly expressing K14, K10, Involucrin, TGM1 and Filaggrin, (b) three perfusable vascular channels with angiogenic sprouts stained with VE-Caderin and Collagen IV, (c) an adjacent microvascular network created via vasculogenesis and connected to the sprouting macrovessels. Histological analysis and immunostaining of CD31, Collagen IV, Perlecan and Laminin proved the integrity of vascular constructs. In order to validate the vascularized skin potential of topical and systemic applications, caffeine and minoxidil, two compounds with different chemical properties, were topically applied to measure skin permeability and benzo[a]pyrene pollutant was systemically applied to evaluate systemic delivery. Our results demonstrated that perfusion of skin reconstructs and the presence of a complex vascular plexus resulted in a more predictive and reliable model to assess respectively topical and systemic applications. This model is therefore aimed at furthering drug discovery and improving clinical translation in dermatology.
- Subjects :
- CD31
Angiogenesis
[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]
[SDV]Life Sciences [q-bio]
0206 medical engineering
Microfluidics
Biomedical Engineering
Neovascularization, Physiologic
Bioengineering
02 engineering and technology
Perlecan
Biochemistry
perfusion
vasculogenesis
Biomaterials
angiogenesis
Vasculogenesis
Tissue engineering
vascularization
medicine
[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]
Skin equivalent
Involucrin
Skin
reconstructed skin
biology
integumentary system
business.industry
General Medicine
021001 nanoscience & nanotechnology
020601 biomedical engineering
3. Good health
medicine.anatomical_structure
tissue engineering
biology.protein
Reconstructed skin Tissue engineering Vascularization Vasculogenesis Angiogenesis Perfusion
Epidermis
0210 nano-technology
business
Biotechnology
Biomedical engineering
Subjects
Details
- Language :
- English
- ISSN :
- 17585082, 17585090, 19373341, and 1937335X
- Database :
- OpenAIRE
- Journal :
- Biofabrication, Biofabrication, 2020, 13 (3), pp.035042. ⟨10.1088/1758-5090/abfca8⟩, Biofabrication, IOP Publishing, 2020, 13 (3), pp.035042. ⟨10.1088/1758-5090/abfca8⟩, Tissue Engineering: Parts A, B, and C, Tissue Engineering: Parts A, B, and C, 2022, 13 (3), pp.S472-S473. ⟨10.1088/1758-5090/abfca8⟩
- Accession number :
- edsair.doi.dedup.....27bec377f7cb4637c892c185438febda
- Full Text :
- https://doi.org/10.1088/1758-5090/abfca8⟩